The Applications of Meloxicam: A Nonsteroidal Anti-Flammatory Drug

1604 Words4 Pages

INTRODUCTION

Meloxicam is a nonsteroidal anti-flammatory drug (NSAIDs) which are a group of drugs to treat pain and/or inflammation. It is an only prescription drug and is available for individuals who have tenderness, swelling and pain caused by the inflammation of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis. Meloxicam functions by inhibiting the effect of chemicals called cyclo-oxygenase (COX) enzymes which are used to make prostaglandins. Prostaglandins are the chemicals that cause pain and inflammation, known as inflammation mediators. By inhibiting the COX enzymes, fewer prostaglandins are produced, resulting in relief of pain. As there are many conditions that has to be followed up when prescribing a drug, this essay will discuss the following based on Meloxicam:
• Absorption and distribution of the drug
• Use of drug in pregnancy and breastfeeding
• Use of drug in renal and hepatic impairment

Absorption and distribution of the drug

The absorption of Meloxicam through oral administration is from the gastrointestinal tract which results in a high availability of 89%. This can be in the form of tablets, oral suspension and capsules and will produce the same bioavailability. However, with different forms of Meloxicam, there will be a difference in the time taken for the mean maximum plasma concentrations to be achieved. Following a single dose of taking Meloxicam in oral suspension form, the mean maximum plasma concentration is achieved in 2 hours whereas for capsules and tablets, it takes about 5-6 hours. This is more effective when taking a single oral dose of 30mg compared with 30 mg IV bolus injection. Dose proportional pharmacokinetics were shown in the range of 5mg to 60 mg when taking single intrave...

... middle of paper ...

...ductus arteriosus: A review. (Obstet Gynecol Surv 1989); 44: pg 541–543.

Oedema – Last updated: 16 April 2014 – Retrieved on: 30 April 2014 from NHS: http://www.nhs.uk/Conditions/Oedema/Pages/Introduction.aspx DrugM. Del Tacca, R. Colucci, M. Fornai, C. Blandizzi - Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Disclosures - Clin Drug Invest. 2002;22(12)

RxList International Drug Index, Published by RxList Inc.
Last reviewed: 13 March 2012 – Retrieved on: 1 May 2014 from: http://www.rxlist.com/mobic-drug/clinical-pharmacology.htm

D. Turck, W. Roth And U. Busch - A Review Of The Clinical Pharmacokinetics Of Meloxicam-British Journal of Rheumatology 1996;35(suppl. 1): pg 13-16

British National Formulary; 65th Edition (Mar 2013) British Medical Association and Royal Pharmaceutical Society of Great Britain, London

More about The Applications of Meloxicam: A Nonsteroidal Anti-Flammatory Drug

Open Document